HBeAg阳性慢性乙型肝炎患者的核苷（t）ide类似物巩固治疗：

StephenW

Nucleos(t)ide analogues consolidation therapy in HBeAg-positive chronic hepatitis B patients: Three years should be preferred
Tao Li  1 , Yan Liang  2 , Meng Zhang  1   3 , Feng Liu  4   5 , Lixin Zhang  1 , Baohua Yang  1 , Lei Wang  1
Affiliations
Affiliations

    1
    Department of Infectious Disease and Hepatolgy, the Second Hospital, Cheeloo College of Medicine, Shandong University.
    2
    Department of Infectious Disease, Jinan Infectious Disease Hospital.
    3
    Department of Hepatolgy, Jinan Infectious Disease Hospital, Cheeloo College of Medicine, Shandong University.
    4
    Department of Hepatolgy, Tianjin Second People's Hospital.
    5
    Tianjin Institute of Hepatology.

    PMID: 33772988 DOI: 10.1111/hepr.13641

Abstract

Aim: To assess the role of consolidation therapy after nucleos(t)ide analogues (NAs) cessation for off-treatment outcome and to explore the optimal consolidation period in HBeAg-positive chronic hepatitis B (CHB) patients.

Methods: We performed a prospective, observational cohort study including HBeAg-positive CHB patients discontinuing NAs. Virological relapse was the primary endpoint of the current study and was defined as a serum HBV DNA more than 104 copies/ml (another assay was performed for confirmation at least 2 weeks later). Propensity score matching analysis (PSM) was used to balance the baseline characteristics between HBeAg-positive CHB patients with different consolidation periods.

Results: A total of 190 HBeAg-positive CHB patients were included. Fifty-four patients relapsed during follow-up and the cumulative relapse rates at years 1, 3, 5 and 10 were 19.5%, 24.1%, 27.2% and 32.1%, respectively. Most patients (61.1%) relapsed in the first 6 months. After PSM, significant lower cumulative relapse rates were observed in patients with consolidation period ≥ 36months compared with patients with consolidation period < 36 months (29.3% vs. 52.8% at year 10, p = 0.012).

Conclusions: NAs cessation after HBeAg seroconversion and long-term consolidation is generally safe and feasible in HBeAg-positive CHB patients. Three years of consolidation should be preferred in clinical practice. This article is protected by copyright. All rights reserved.

Keywords: cessation; chronic hepatitis B; consolidation therapy; nucleos(t)ide analogues.

This article is protected by copyright. All rights reserved.

StephenW

HBeAg阳性慢性乙型肝炎患者的核苷（t）ide类似物巩固治疗：首选三年
陶莉1，闫亮2，张萌1 3，刘凤4 5，张立新1，杨宝华1，王磊1
隶属关系
隶属关系

    1个
    山东大学奇卢医学院第二医院传染病和肝病科。
    2个
    济南市传染病医院传染病科。
    3
    山东大学奇鲁医学院济南传染病医院肝病科
    4
    天津市第二人民医院肝科。
    5
    天津市肝病研究所。

    PMID：33772988 DOI：10.1111 / hepr.13641

抽象的

目的：评估核糖核苷酸类似物（NAs）停止后巩固治疗对非治疗结局的作用，并探讨HBeAg阳性慢性乙型肝炎（CHB）患者的最佳巩固期。

方法：我们进行了一项前瞻性，观察性队列研究，其中包括停用NAs的HBeAg阳性CHB患者。病毒学复发是当前研究的主要终点，定义为血清HBV DNA大于104拷贝/ ml（至少在2周后进行另一次测定以确认）。倾向得分匹配分析（PSM）用于平衡具有不同巩固期的HBeAg阳性CHB患者之间的基线特征。

结果：总共包括190例HBeAg阳性CHB患者。 54例患者在随访期间复发，在1、3、5和10年的累积复发率分别为19.5％，24.1％，27.2％和32.1％。大多数患者（61.1％）在头6个月内复发。 PSM后，巩固期≥36个月的患者的累积复发率明显低于巩固期<36个月的患者（29.3％比10年的52.8％，p = 0.012）。

结论：HBeAg阳性CHB患者在HBeAg血清转化和长期巩固后停止NAs通常是安全可行的。临床实践中应首选三年巩固治疗。本文受版权保护。版权所有。

关键词：戒烟；戒烟慢性乙型肝炎巩固疗法；核苷（核苷酸）类似物。

本文受版权保护。版权所有。